Clinical Trials Directory

Trials / Completed

CompletedNCT00068445

Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

The Efficacy of Lamotrigine in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
131 (actual)
Sponsor
Alliance for Clinical Trials in Oncology · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Lamotrigine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. It is not yet known whether lamotrigine is effective in treating peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized phase III trial is studying how well lamotrigine works in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy caused by chemotherapy in patients with cancer.

Detailed description

OBJECTIVES: * Compare the efficacy of lamotrigine vs placebo in reducing pain and symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. * Compare symptom distress, mood states, functional abilities, and overall quality of life of patients treated with these agents. * Determine the toxic effects of lamotrigine in these patients. OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are stratified according to neurotoxic chemotherapy received (taxanes vs platinum-based compounds vs vinca alkaloids vs combination vs other), status of neurotoxic chemotherapy (actively receiving therapy vs discontinued or completed), and duration of pain or neuropathy symptoms (1-3 months vs 3-6 months vs more than 6 months). Patients are randomized to 1 of 2 treatment arms.

Conditions

Interventions

TypeNameDescription
DRUGlamotrigine
OTHERPlacebo

Timeline

Start date
2004-02-01
Primary completion
2006-05-01
Completion
2013-11-01
First posted
2003-09-11
Last updated
2018-05-04
Results posted
2018-05-04

Locations

23 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00068445. Inclusion in this directory is not an endorsement.